Business Categories Reports Podcasts Events Awards Webinars
Contact My Account About

Kenvue, J&J’s Consumer Health Unit, Files for an IPO

Published January 17, 2023
Published January 17, 2023
Johnson & Johnson

Johnson & Johnson's consumer health segment Kenvue has filed to be listed as an independent company under the ticker symbol KVUE. The filing on the New York Stock Exchange comes a year after the healthcare and personal care giant voiced its intention to split into two companies.

The filing indicates Kenvue aims to raise $100 million, which is likely a placeholder. Research firm Renaissance Capital estimates the offering could raise as much as $5 billion, making it the largest company on file in the IPO pipeline. As a unit of J&J, Kenvue reported over $15 billion in consumer health sales in 2021, with profits totaling $2 billion.

WHO: Kenvue claims to be the world's largest pure-play consumer health company by revenue, operating across three segments: self-care, skin health and beauty, and essential health. Its differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Aveeno, and Dr.Ci:Labo, among others. Ten of its brands had over $400 million in net sales in 2021, and the company currently holds five #1 brand positions across major categories globally, in addition to many #1 brand positions locally.

IN ITS OWN WORDS: In its filing, Kenvue says it's "the world's largest pure-play consumer health company by revenue," with $15.1 billion in 2021 net sales. The company said each of its products are No. 1 in their respective market sectors, such as Johnson's spot as the No. 1 baby toiletries brand globally. The company's market standing, as well as its "competitive financial portfolio," are some strengths Kenvue hopes will reel in investors.

WHY: The planned separation is expected to be completed later this year, and J&J will remain focused on pharmaceutical and medical devices.

DETAILS:

  • The unit has filed to be listed as an independent company under the ticker symbol KVUE.
  • J&J will continue to own at least 80.1% of the voting power of Kenvue's shares upon completion of the offering. 
  • Aveeno, Neutrogena, Johnson's, Tylenol, Dr.Ci:Labo, and Band-Aid will be among the brands included in Kenvue's portfolio.
  • In its filing, Kenvue noted that LTL Management, the subsidiary J&J set up to enact a Texas two-step bankruptcy, would remain as part of J&J and not Kenvue.
  • Goldman Sachs and J.P. Morgan are the underwriters for the offering.

You've reached your limit.

Want to continue reading this article and others just like it?

Subscribe to BeautyMatter and access the most current beauty intelligence and news updates.

Subscribe

Already a member, login here.